Global primary aldosteronism market size was valued at USD 1.14 billion in 2022. The primary aldosteronism market industry is projected to grow from USD 1.23 billion in 2023 to USD 2.24 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.80% during the forecast period (2023 - 2032). Aldosteronism is a hormone in the human body. The adrenal glands regulate sodium and potassium in the blood through this hormone. However, in some individuals the secretion of this hormone is high. Due to this blood pressure, sodium and blood volume is high. The treatment of this condition is essential as the risk of stroke and heart disease is high. The availability of aldosteronism treatment is high in recent years. Earlier, the identification of this condition is low. Awareness about the disease is less in earlier years. However, drugs and treatments available for the disease are surging. The oral salt loading test is growing every year. The easy access for the treatment of primary is increasing growth for primary aldosteronism market.
Due to the high secretion of this hormone kidney, salvia glands, sweat glands have high salt content. Today, the pharmacies supplying the aldosteronism drugs are rising. Also, many regions have favourable scenarios that will bring positive changes in the market. Extensive research is happening in the aldosteronism market. Due to noncancerous tumours and defects in genes is another underlying condition in the market. Hyperactivity and hyper conditions are some of the other conditions of this disorder. The non-surgical segment of the primary aldosteronism market is witnessing high growth in the forecast period.
Covid analysis
The outbreak of covid 19 is causing plenty of difficulties in global industries. The treatment of Aldosteronism is witnessing a downfall in the forecast period. During this period, covid patient care is the prime focus of hospitals. Treating new covid cases and reducing the death rate is the major health sector operations. Further, the development of a vaccine is a crucial operation. The treatment for the disorders is declining in this period.
The patients visiting hospitals for other conditions have significantly reduced during this period. The test, screening, treatment, drugs market of Aldosteronism is facing a downfall during this pandemic. Due to global lockdowns and restrictions treatment for this condition is delaying. The supply chain distributions to transport treatment product related to this condition is diminishing. However, Aldosteronism is undergoing extensive research. More study about the condition will lead to plenty of future developments.
Market dynamics
The prevalence of primary aldosteronism is a crucial driver for the primary aldosteronism market. A sedentary lifestyle is a reason for more aldosteronism. It is a hormonal disorder that is stirred by plenty of factors. High blood pressure and hypertension are triggering Primary Aldosteronism. Also, busy lifestyle stressful condition is another factor for the disorder. In the upcoming years, the case of Aldosteronism is expected to rise immensely. The growing geriatric population is another demand driving factor of the primary aldosteronism market. The age’s population is often prone to hormonal imbalance. Also, the easy indication methods of this condition in aged individuals are rising.
It is a crucial driver that increases the adoption rate of the primary aldosteronism market. Awareness about Aldosteronism is a major diver for the primary aldosteronism market. Aldosteronism can lead to other health complications without proper treatment. High blood pressure, heart disease, kidney problems and other issues are common with this commission. More awareness about the disease is diving most of the population for the Aldosteronism test. Also, the testing and treatments for Aldosteronism are high. Due to this, the demand rate is continuously surging. All these factors will contribute to the high profitability of the primary aldosteronism market. The exposure for the market will reach its peak in upcoming years.
The efforts to invest in new drugs for Aldosteronism are rising in many regions. It is a significant factor that creates more development possibilities for the primary aldosteronism market. The launch of new therapeutic drugs by key players will increase the growth rate. All these developments in the market are possible through high research and development. The R&D investments for the market are rising. Also, Aldosteronism is a less studied condition. More research will lead to a better understanding of this disease. Also, efficient treatment is possible through this research.
The growing research in the market will escalate the overall expansion rate in the forecast period. Due to more awareness, the high adoption of the treatment will bring favourable changes in the primary aldosteronism market. Also, the Aldosteronism market provides both surgical and non-surgical treatments. It offers plenty of choices for the patients to choose from. However, the developments in non-surgical Aldosteronism are high in the forecast period. All these factors will bring exceptional, primary aldosteronism market growth possibilities.
The lack of awareness about the primary Aldosteronism market is a major restraint. Aldosteronism is a condition that is less known in developing nations and many regions. Many think of Aldosteronism as a normal rise in blood pressure. However, no proper treatment for the disorder can lead to an increased imbalance in hormones. More research and awareness programs for the market are happening in the forecast period.
It is expected to increase the effects of this medical condition. As per the primary aldosteronism market analysis, less awareness will lead to low adoption of Aldosteronism treatment. Also, the lack of proper treatment in several health sectors for the condition is another restraint in the primary aldosteronism market. These factors can hamper the overall demand in the forecast period.
There are side effects for primary Aldosteronism treatment. These side effects pose a challenge to the primary Aldosteronism market. Especially, therapeutics drugs can affect the patient with visible side effects. As it is a hormonal condition, the hormones in the body can change. Due to this breast enlargement, menstrual irregularities and impotence are common.
These side effects hinder the demand for the market in the forecast period. Also, there are several risks related to the other forms of Aldosteronism treatment. Excessive bleeding due to surgical Aldosteronism is a concerning factor of the primary aldosteronism market. These side effects create fear in patients to adapt to the treatment. These side effects and market challenges can hamper the overall expansion rate.
Growth of the primary aldosteronism is constantly surging in the forecast period. Several factors stir the overall growth of the primary aldosteronism market. The increasing awareness about this disease is leading to more adoption. Also, the treatments available for aldosteronism are growing in many regions.
Further, the growth of the geriatric population is a major cause of the high demand for aldosteronism treatment and surgeries. The R&D investments will bring a favourable impact on the primary aldosteronism market. With increasing research, product launches and innovations are expected to create promising growth possibilities for the market. The primary aldosteronism market trends remain positive.
North America is an excelling regional player of the primary aldosteronism market. The developed health infrastructure in this region creates massive demand. The patient base is wide in this region. Also, high health expenditure leads to more growth in the aldosteronism market.
It is a region having a favourable market condition. Production of drugs, therapies, and treatments for aldosteronism is high. The awareness about this condition is higher in America. Also, it is a region that has advanced treatment for aldosteronism. All these factors double the growth of the overall aldosteronism market in North America.
Segment overview
By treatment type
By end-users
Competitive landscape
The competition in the primary aldosteronism treatment industry is moderate in the forecast period. In the upcoming years, the entry of new key players is expected in the market. It can intensify the competition in the primary aldosteronism market. Easy treatment, low-cost drugs are the key strategies of market players. Also, market acquisition, expansion and partnerships will happen in the market.
Regional analysis
The aldosteronism market is segmented into Asia Pacific, Europe and North America. North America is a predominant regional player with higher growth. The prevalence of tumour and aldosteronism cases is higher in this region. Further, the availability of drugs and treatment is higher in this region. The well-established health facilities lead to exceptional treatment for the disease. Europe is another largest key player with high demand.
The health expenditure is higher in Europe. It leads to more research and development in the region. The awareness about aldosteronism is less in Asia pacific. However, the market expansion rate and adoption of treatments are higher. India, chain and jape are the key contributors to the market.
The key players of the primary aldosteronism market are
Recent developments
Report overview
| Report Attribute/Metric | Details |
| Market Size (2032) | 2.24 Billion |
| CAGR | 5.80% |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Indications, Diagnosis, Treatment and End users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol Laboratories Ltd (England), CMP Pharma. (U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K), Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and others. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Increasing prevalence of primary aldosteronism· The growing geriatric population |
Primary Aldosteronism Market Highlights:
Frequently Asked Questions (FAQ) :
primary aldosteronism market is projected to grow at approximately 5.80% CAGR during the assessment period (2023-2032).
Increasing prevalence of the condition and the rising per capita healthcare expenditure, are major tailwinds pushing the growth of the primary aldosteronism market.
Lack of awareness and risks involved with the corrective surgeries, such as excessive bleeding, infection, and anesthesia reaction, are major growth impeder for the primary aldosteronism market.
North America holds the largest share in the primary aldosteronism market, followed by Europe and the Asia Pacific, respectively.
Pfizer Inc. (U.S.), Bristol Laboratories Ltd (UK), Sun Pharmaceutical Industries Ltd. (India), CMP Pharma. (U.S.), Siemens AG (Germany), Shimadzu Corporation (Japan), Koninklijke Philips N.V. (The Netherlands), Canon Inc. (Japan), and GE Healthcare (UK), are some of the top players operating in the primary aldosteronism market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
